This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Initial dopaminergic therapy for Parkinson disease (PD) with an agonist, rather than levodopa, is associated with a lower risk of mild dyskinesias and motor fluctuations in the first 5 years of treatment.1,2 This short-term advantage of agonists is offset by providing less symptom relief and a higher incidence of adverse effects. The American Academy of Neurology practice parameter on initiating treatment for PD concluded that therapy needs to be individualized and that either levodopa or an agonist is acceptable.3 Despite this, “levodopa phobia”4 abounds: many are under the impression that initial treatment of PD should be an agonist and that it is advantageous to delay levodopa. Similarly, patients are often misinformed that levodopa “stops working” after 5 years and inappropriately view the initiation of levodopa as starting down a slippery slope.
Is levodopa phobia justified? Until recently, little was known about how the initial choice of a dopaminergic agent influences the long-term manifestations of PD. If starting with an agonist reduced the incidence of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Agonist or levodopa for Parkinson disease?: Ultimately, it doesn't matter; neither is good enough
- Reply from the authors
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
